Related Experiment Videos
Early virologic response with pegylated interferons.
1Istituto di Clinica Medica 1, University of Palermo, Italy. craxanto@unipa.it
Summary
Early stopping rules for antiviral therapy can be applied at 12 weeks. Maximizing the negative predictive value is key to minimize discontinuing treatment in patients who might ultimately respond to therapy.
Area of Science:
- Hepatology
- Virology
- Clinical Pharmacology
Background:
- Early evaluation of viral response is recommended to reduce antiviral treatment morbidity and costs.
- Development of early stopping rules assumes minimization of treatment discontinuation in potentially responsive patients.
- Sustained virological response is a primary clinical goal in defining early stopping rules.
Purpose of the Study:
- To evaluate the feasibility of early stopping rules for antiviral therapy.
- To determine the optimal predictive value for defining early stopping rules.
- To assess the impact of early stopping on sustained virological response rates.
Main Methods:
- Analysis of viral response at 12 weeks of antiviral therapy.
- Comparison of rules maximizing negative predictive value versus positive predictive value.
- Evaluation of sustained virological response rates based on different stopping criteria.
Main Results:
- Early stopping rules can be implemented as early as week 12 for PEG-IFN alpha-2b or alpha-2a combination therapy.
- Maximizing negative predictive value minimizes the loss of potential responders.
- Optimizing positive predictive value reduces immediate costs but may exclude some patients who would benefit from continued therapy.
Conclusions:
- Treatment decisions for antiviral therapy can be made at week 12.
- Individualized treatment decisions should consider viral assay variability, patient preferences, and ongoing research.
- Minimizing loss of potential responders is crucial for maximizing sustained virological response.